ASGCT, NORD Partner for CME Program

ASGCT Staff - April 19, 2021

ASGCT has partnered with NORD to offer a two-part virtual CME program, The Time Is Now: Understanding Gene Therapy, Applications, and Implications, to educate clinicians on gene therapy.

ASGCT members and those in the gene therapy community pursuing CME credits will be excited to learn about the Society's latest partnership with the National Organization for Rare Disorders (NORD), The Time Is Now: Understanding Gene Therapy, Applications, and Implications. This two-part series begins on Thursday, April 22 at 2 p.m. ET, and will reconvene on Thursday, April 29 for part two.

Register for This CME Event

This CME-providing program is designe for a clinical audience to: 

  • Explain the potential of gene‐based treatment approaches to change the disease course for patients with genetic conditions
  • Discuss different types of current and emerging gene‐based therapies
  • Summarize the key steps of development programs for gene therapies, identifying how and why some programs may differ from others
  • Explain the role of the FDA in providing regulatory oversight from development to post marketing

The Time Is Now: Understanding Gene Therapy, Applications, and Implications

Live Day 1: April 22, 2021  |  2 p.m. ET

Gene Transfer, Editing, Silencing and RNA Based‐Approaches: What, When and How?

Day 1, Session 2: 3 p.m. ET

Clinical Development and Regulatory Oversight of Gene-Based Therapies From Development to Post-Marketing

Live Day 2: April 29, 2021

Related Articles


Learn About Gene Therapy for GM1 Gangliosidosis

ASGCT Staff - July 29, 2021

Learn How mRNA Vaccines Offer Protection from COVID-19

ASGCT Staff - December 30, 2020

Understanding Ethical Concerns About Germline Gene Editing

ASGCT Staff - December 16, 2020

Viewing Breast Cancer with a CRISPR Lens: The Potential of Gene-Editing Treatment

Eoghan J. Mulholland, Ph.D. - October 20, 2020